Skip to main content
IVVD
NASDAQ Life Sciences

Invivyd Reports Q1 2026 Results, Secures $20M via ATM, Advances VYD2311 Program

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.4
Mkt Cap
$415.722M
52W Low
$0.483
52W High
$3.07
52W Position info
190% above low
Off High info
54% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

IVVD has more than doubled off its 52-week low of $0.483.

Summary

Invivyd reported increased Q1 2026 net loss and operating expenses, but secured $20 million via an ATM offering to extend its cash runway while advancing its VYD2311 clinical program with positive regulatory and safety updates.


Key Events · Earnings and Guidance · IVVD

  • Q1 2026 Financial Results

    Reported a net loss of $41.4 million for Q1 2026, significantly higher than $16.3 million in Q1 2025, primarily due to increased R&D and SG&A expenses. PEMGARDA net product revenue grew 22% year-over-year to $13.7 million.

  • Capital Raise via ATM Offering

    Raised approximately $20 million in gross proceeds through an at-the-market (ATM) offering facility in April 2026, bolstering cash and cash equivalents to support operations through the VYD2311 pivotal data readout.

  • VYD2311 Clinical Program Progress

    The DECLARATION pivotal trial for VYD2311 saw rapid enrollment and positive Independent Data Monitoring Committee (IDMC) recommendations, including reduced post-dose monitoring time and expanded patient eligibility. FDA alignment was also achieved for pediatric and comparative safety trials.

  • DECLARATION Data Anticipated Q3 2026

    Top-line data for the DECLARATION pivotal clinical trial for VYD2311 is now anticipated in Q3 2026, a modest shift of approximately two months from original 'mid-year' guidance, due to trial upsizing.


Analysis · IVVD · Life Sciences

Invivyd, Inc. reported a significant increase in net loss for Q1 2026, more than doubling year-over-year, driven by higher R&D and SG&A expenses as the company advances its lead VYD2311 program. Despite this increased cash burn, the company successfully raised approximately $20 million through an at-the-market (ATM) offering in April 2026, which is crucial for extending its cash runway, especially given the 'going concern' warning in its last 10-K. Positive clinical updates for VYD2311, including favorable IDMC recommendations and FDA alignment for pediatric and comparative safety trials, provide a clearer path forward, though top-line data for the DECLARATION trial is now anticipated in Q3 2026, a slight delay.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IVVD was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415.7M. The 52-week trading range was $0.48 to $3.07. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IVVD - Latest Insights

IVVD
Nov 16, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.5867
Real-time Price: $0.458 info
Change: -$0.1287 (-22%) info
Market Cap: $131.822M info
IVVD
Nov 16, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.562
Real-time Price: $0.458 info
Change: -$0.104 (-19%) info
Market Cap: $131.822M info
IVVD
Nov 16, 2026, 7:02 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.5731
Real-time Price: $0.458 info
Change: -$0.1151 (-20%) info
Market Cap: $131.822M info
IVVD
Sep 29, 2026, 7:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9635
Real-time Price: $0.458 info
Change: -$0.5055 (-52%) info
Market Cap: $131.822M info
IVVD
Sep 29, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.16
Real-time Price: $0.458 info
Change: -$0.7018 (-61%) info
Market Cap: $131.822M info